section name header

Pronunciation

sit-a-GLIP-tin

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: enzyme inhibitors

Indications

REMS


Action

  • Inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which slows the inactivation of incretin hormones, resulting in increased levels of active incretin hormones. These hormones are released by the intestine throughout the day and are involved in regulation of glucose homeostasis. Increased/prolonged incretin levels result in an increase in insulin release and decrease in glucagon levels.
Therapeutic effects:
  • Improved control of blood glucose.

Pharmacokinetics

Absorption: 87% absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Undergoes minor metabolism by the liver via the CYP3A4 and CYP2C8 isoenzymes to inactive metabolites; 87% excreted in the urine (79% as unchanged drug), with 13% excreted in the feces.

Half-Life: 12.4 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POrapid1–4 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: HF

Derm: bullous pemphigoid, rash, STEVENS-JOHNSON SYNDROME (SJS), urticaria

EENT: nasopharyngitis

GI: diarrhea, nausea, PANCREATITIS

GU: acute renal failure

MS: arthralgia, back pain, myalgia, RHABDOMYOLYSIS

Neuro: headache

Resp: upper respiratory tract infection

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Januvia

Pill Image

sitagliptin_195-8758.jpg